Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients

被引:4
|
作者
Naicker, Derisha [1 ]
Reed, Peter W. [2 ]
Ronaldson, Jane [1 ]
Kara, Tonya [1 ]
Wong, William [1 ]
Prestidge, Chanel [1 ]
机构
[1] Starship Childrens Hosp, Dept Pediat Nephrol, Pk Rd,Private Bag 92024, Auckland 1142, New Zealand
[2] Starship Childrens Hosp, Childrens Res Ctr, Auckland, New Zealand
关键词
Calcineurin inhibitor; Generic Immunosuppression; Renal; Tacrolimus; Transplantation; IMMUNOSUPPRESSION; PROGRAF; DRUGS;
D O I
10.1007/s00467-017-3707-3
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Bioequivalence between Tacrolimus Prograf (R) and generic tacrolimus formulations has been demonstrated in adult populations,however clinical experience and safety data regarding generic tacrolimus in pediatric transplant recipients is limited. This study aimed to evaluate conversion from Tacrolimus Prograf (R) to Sandoz (R) in pediatric renal transplant recipients nationwide. The primary outcome was a change in mean trough tacrolimus concentration. Additionally, changes in tacrolimus intra-patient coefficient of variation (CoV), allograft function, requirement for dose adjustments, and episodes of biopsy-proven rejection were evaluated. Methods Retrospective cohort study in 37 pediatric renal transplant recipients who switched to Tacrolimus Sandoz (R). Each patient had three pre-conversion tacrolimus trough and creatinine concentrations within the 4 months prior and three post-conversion concentrations on day 3, 10, and the next subsequent level. Mean pre-and post-conversion tacrolimus trough concentrations and glomerular filtration rate (eGFR) were calculated. Tacrolimus concentration, CoV, and creatinine differences were compared by paired t test. Results Thirty-seven patients (41% females, age 3-18 years) were included. Average intra-patient difference in trough tacrolimus concentration was 0.05 mu g/l (95% CI -0.37 to 0.47). Average intra-patient difference in eGFR was -1.20 ml/min/1.73(2) (95% CI -3.53 to 1.13). Three patients had acute rejection during 12 months post-conversion compared to none during 12 months pre-conversion. Conclusions Pediatric renal transplant recipients can be converted from Tacrolimus Prograf (R) to Sandoz (R) with negligible change in trough concentration, dose adjustments, or immediate allograft function. Of concern was the number of acute rejection episodes, however non-adherence contributed to at least one episode and this difference was determined clinically and statistically not significant.
引用
收藏
页码:2125 / 2131
页数:7
相关论文
共 50 条
  • [31] Conversion of Twice-Daily Tacrolimus to Once-Daily Tacrolimus Formulation in Stable Pediatric Kidney Transplant Recipients: Pharmacokinetics and Efficacy
    Min, S. I.
    Ha, J.
    Kang, H. G.
    Ahn, S.
    Park, T.
    Park, D. D.
    Kim, S. M.
    Hong, H. J.
    Min, S. K.
    Ha, I. S.
    Kim, S. J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (08) : 2191 - 2197
  • [32] CONVERSION OF TWICE-DAILY TACROLIMUS TO ONCE-DAILY TACROLIMUS FORMULATION IN STABLE PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS: PHARMACOKINETICS AND EFFICACY
    Min, Sang-Il
    Kang, Hee-Kyoung
    Ha, Jongwon
    Ha, Il-Soo
    Kim, Sang Joon
    TRANSPLANT INTERNATIONAL, 2013, 26 : 125 - 125
  • [33] Conversion of Twice-Daily Tacrolimus to Once-Daily Tacrolimus in Stable Pediatric Kidney Transplant Recipients: Interim Pharmacokinetic Analysis
    Min, S. I.
    Ahn, S.
    Park, T.
    Park, D.
    Kim, S. M.
    Min, S. -K.
    Kang, H. K.
    Ha, I. S.
    Kim, S. J.
    Ha, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 442 - 442
  • [34] CONVERSION OF TWICE-DAILY TACROLIMUS TO ONCE-DAILY TACROLIMUS FORMULATION IN STABLE PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS: PHARMACOKINETICS AND EFFICACY
    Min, Sang-Il
    Kang, Hee-Kyoung
    Ha, Jongwon
    Ha, Il-Soo
    Min, Seung-Kee
    Kim, Sang Joon
    PEDIATRIC TRANSPLANTATION, 2013, 17 : 44 - 44
  • [35] Comparison of Dose Requirements of Sandoz™ Generic Tacrolimus with Brand Prograf® in Kidney Transplant Recipients
    Dick, T. B.
    Raines, A. A.
    Van der Werf, W.
    Alonso, D.
    Fujita, S.
    Stinson, J. B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 354 - 354
  • [36] Dose Conversion Factor Between Cyclosporine and Tacrolimus in Pediatric Heart Transplant Recipients
    Notaro, E.
    Brown, L.
    Albers, E.
    Law, S.
    Law, Y.
    Kemna, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 235 - 235
  • [37] Dose conversion factor between cyclosporine and tacrolimus in pediatric heart transplant recipients
    Notaro, Eliza
    Brown, Lisa
    Albers, Erin
    Law, Sabrina
    Kemna, Mariska
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (07): : 766 - 768
  • [38] Impact of Conversion From Advagraf to Twice-Daily Generic Tacrolimus in Kidney Transplant Recipients: A Single-Center Study
    Melo, M. J.
    Goncalves, J.
    Guerra, J. O.
    Santana, A.
    Nascimento, C.
    TRANSPLANTATION PROCEEDINGS, 2015, 47 (04) : 911 - 913
  • [39] Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in de Novo Pediatric Kidney Transplant Recipients
    Zhao, Wei
    Elie, Valery
    Roussey, Gwenaelle
    Brochard, Karine
    Niaudet, Patrick
    Deschenes, Georges
    Cochat, Pierre
    Cloarec, Sylvie
    Andre, Jean Luc
    Tsimaratos, Michel
    Bensman, Albert
    Fakhoury, May
    Jacqz-Aigrain, Evelyne
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 662 - 662
  • [40] The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients
    Mads Juul Madsen
    Troels K. Bergmann
    Kim Brøsen
    Helle Charlotte Thiesson
    Drugs in R&D, 2017, 17 : 279 - 286